PATENT CLAIM ANALYSIS

Application Number: 16109337
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-06
Patent Classification: ["544", "262000"]

Abstract:
The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

Claim (Index 43):
A method for the treatment of lymphoid lineage, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma, hematopoietic tumors of myeloid lineage, multiple myelomas, smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, or extramedullary plasmacytoma in a subject in need thereof, the method comprising administering to the subject an effective amount of (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 4-methylbenzenesulfonate having an enantiomeric excess of at least 95%.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 96.0
- Lexical Diversity: 1.23333
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15283515', '13933856', '15480128', '14832962', '14440139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8166723046772815
- 35 USC 102 Novelty (BERT): 0.6304644396955308
- Combined Prediction Score: 0.7980515181791064
- Mean Citation Score: 544.4503659999998
- Max Citation Score: 583.6667
- Similarity Product: 560.3437457418621

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test